Nontuberculous mycobacterial lung disease - Symptoms, Causes, Treatment & Prevention

Overview

Nontuberculous mycobacterial (NTM) lung disease is an infection of the respiratory tract caused by mycobacteria that do not produce tuberculosis (TB) or leprosy. Over 190 species of NTM have been identified; the most common culprits in lung disease are Mycobacterium avium complex (MAC), Mycobacterium abscessus complex, and Mycobacterium kansasii.

Unlike TB, NTM are found ubiquitously in soil, water, and biofilms. Most people inhale low numbers of these organisms daily without illness. Disease develops when the bacteria multiply in the lungs and provoke chronic inflammation.

Prevalence: In the United States, the prevalence of NTM lung disease is estimated at 5–10 cases per 100,000 persons, and it appears to be rising—one report showed a ~8 % annual increase from 2007‑2017 (CDC, 2020). Women aged 50‑70, people with underlying lung disease, and individuals of Asian descent are disproportionately affected.

Symptoms

Symptoms develop slowly and may be mistaken for asthma, COPD, or chronic bronchitis. The most common manifestations include:

• Chronic cough – usually dry or minimally productive, lasting >8 weeks.
• Fatigue & low‑grade fever – often worse in the evenings.
• Weight loss & loss of appetite – unintended loss of >5 % body weight.
• Shortness of breath – especially on exertion; may progress to resting dyspnea.
• Chest pain – dull, pleuritic, or related to coughing.
• Hemoptysis (coughing up blood) – can be minor streaks or larger volumes.
• Night sweats – less common than in TB but reported in up to 20 % of patients.
• Wheezing or crackles on auscultation – reflective of airway inflammation.

Because symptoms are nonspecific, a high index of suspicion is essential, particularly in people with known risk factors.

Causes and Risk Factors

What causes NTM lung disease?

NTM are environmental mycobacteria. Disease occurs when:

1. Inhaled organisms reach the lower airways.
2. The host’s local defense mechanisms (mucociliary clearance, macrophage function) are impaired.
3. The bacterial strain possesses virulence traits that allow it to resist killing and form biofilms.

Who is at higher risk?

• Underlying lung disease – bronchiectasis, COPD, cystic fibrosis, prior TB, or sarcoidosis.
• Immunosuppression – HIV/AIDS (especially CD4 <200), biologic agents (TNF‑α inhibitors), long‑term steroids.
• Women with slender body habitus – “Lady Windermere” syndrome, a form of MAC infection that preferentially affects middle‑aged, non‑smoking women.
• Genetic predispositions – mutations in CFTR, ciliary genes, or IFN‑γ pathway.
• Occupational/ environmental exposure – hot tubs, aerosolized water sources, gardening, or living in regions with high NTM soil content.
• Age – incidence rises after age 50.

Diagnosis

Diagnosing NTM lung disease requires a combination of clinical, radiographic, and microbiologic criteria (American Thoracic Society/Infectious Diseases Society of America, 2020).

1. Clinical assessment

• Document persistent respiratory symptoms for ≥3 months.
• Identify risk factors and exclude alternative diagnoses (e.g., TB, malignancy).

2. Imaging

• Chest X‑ray – may show nodular infiltrates or cavitary lesions, but sensitivity is limited.
• High‑resolution CT (HRCT) – the gold standard. Typical patterns:
  • Fibrocavitary disease – upper‑lobe cavities, similar to TB.
  • Nodular‑bronchiectatic disease – multifocal bronchiectasis with small nodules, often in the mid‑lung zones.

3. Microbiologic confirmation

At least one of the following is required:

• Two positive sputum cultures from separate expectorations.
• One positive bronchial wash/bronchoalveolar lavage (BAL) culture.
• Biopsy of lung tissue showing histopathologic features (granulomas, necrosis) plus a positive culture.

4. Laboratory tests

• Acid‑fast bacilli (AFB) smear – rapid but not species‑specific.
• Species identification – PCR, line‑probe assay, or MALDI‑TOF; essential for selecting therapy.
• Drug‑susceptibility testing – especially for M. abscessus and macrolide‑resistant MAC.

Treatment Options

Therapy is prolonged (12‑24 months) and should be individualized based on species, drug susceptibility, disease severity, and patient tolerance.

1. Antibiotic regimens

Species	Standard Regimen (≥12 mo)	Key Drugs
MAC (M. avium, M. intracellulare)	Three‑drug macrolide‑based	Clarithromycin/azithromycin + ethambutol + rifampin
M. abscessus complex	Induction → Consolidation	IV amikacin + imipenem + azithromycin (induction 4‑8 wk) then oral macrolide + tigecycline/linezolid (if susceptible)
M. kansasii	Three‑drug	Rifampin + isoniazid + ethambutol (≥12 mo)

Therapy is guided by susceptibility; macrolide resistance is a poor prognostic factor and often necessitates alternative agents (e.g., clofazimine, bedaquiline).

2. Adjunctive measures

• Airway clearance techniques – chest physiotherapy, oscillatory positive‑pressure devices.
• Bronchodilators for co‑existing COPD or asthma.
• Nutritional support – high‑calorie, protein‑rich diet.
• Management of comorbidities (e.g., GERD) that exacerbate cough.

3. Surgical options

Reserved for localized disease refractory to medical therapy, severe hemoptysis, or when a cavity provides a nidus for infection. Resection (lobectomy or segmentectomy) can improve outcomes in carefully selected patients.

4. Monitoring

Regular follow‑up includes:

• Sputum cultures every 1‑2 months until conversion (three consecutive negatives).
• HRCT at baseline, 6‑month intervals, and after treatment completion.
• Liver function tests and audiograms (for aminoglycosides) every 1‑3 months.

Living with Nontuberculous Mycobacterial Lung Disease

Daily Management Tips

• Medication adherence – use pillboxes, set alarms, and keep a treatment diary.
• Airway clearance – perform chest physiotherapy twice daily; consider devices like Acapella or Flutter.
• Hydration – drink ≥2 L water daily to keep secretions thin.
• Nutrition – aim for 30‑35 kcal/kg/day; add supplements if weight loss persists.
• Exercise – low‑impact activities (walking, stationary bike) improve lung capacity and mood.
• Avoid aerosolized water sources – skip hot‑tub use, use filtered water for respiratory devices.
• Vaccinations – stay up‑to‑date with influenza, COVID‑19, and pneumococcal vaccines to prevent secondary infections.
• Smoking cessation – eliminates a major irritant and improves mucociliary clearance.
• Psychosocial support – join support groups, consider counseling; chronic disease can cause anxiety and depression.

Prevention

Because NTM are ubiquitous, complete avoidance is impossible, but risk can be lowered:

• Maintain good water hygiene – use filtered or boiled water for inhalation devices.
• Install UV or filtration systems on household water supplies if you have a high‑risk condition.
• Use protective masks during gardening or dust‑generating activities.
• Promptly treat chronic lung conditions (e.g., bronchiectasis) to improve clearance.
• Limit exposure to hot tubs, steam rooms, and indoor pools unless properly disinfected.
• Regular medical follow‑up for known risk groups (e.g., cystic fibrosis) to detect early colonization.

Complications

If untreated or inadequately treated, NTM lung disease can lead to:

• Progressive bronchiectasis – irreversible airway damage, recurrent infections.
• Severe hemoptysis – airway erosion or cavitary rupture; may require bronchial artery embolization.
• Respiratory failure – especially in advanced COPD or CF.
• Pulmonary fibrosis – scarring from chronic inflammation.
• Disseminated disease – rare, but can occur in severely immunocompromised hosts.
• Drug toxicity – liver injury, ototoxicity, nephrotoxicity leading to treatment interruption.

When to Seek Emergency Care

---

Sources: Mayo Clinic, Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, ATS/IDSA Guidelines (2020), Clinical Infectious Diseases journal.